Premium
Analysis of cysteinyl leukotrienes in human urine: enhanced excretion in patients with liver cirrhosis and hepatorenal syndrome *
Author(s) -
HUBER M.,
KÄSTNER S.,
SCHÖLMERICH J.,
GEROK W.,
KEPPLER D.
Publication year - 1989
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.1989.tb00195.x
Subject(s) - hepatorenal syndrome , leukotriene , cirrhosis , urine , medicine , endocrinology , creatinine , leukotriene e4 , liver disease , radioimmunoassay , chemistry , asthma
. The cysteinyl leukotrienes, comprising leuk‐otriene C 4 and its metabolites, are biologically most active mediators, eliminated from the blood circulation by the liver and the kidneys. The urine of normal subjects and of patients with hepatic and/or renal failure was analysed for endogenous cysteinyl leukotrienes. The leukotriene metabolites were separated by reversed‐phase high‐performance liquid chromatography and subsequently quantified by radioimmunoassay. Leukotreine E 4 was detected in all urine samples analysed. Its mean concentration increased from 0.3 nmol I ‐1 in healthy subjects to 0.8 nmol 1 ‐1 in patients with liver cirrhosis. In patients with hepatorenal syndrome leukotriene E 4 averaged 7.8 nmol I ‐1 ; in addition, N ‐acetyl‐leukotriene E 4 was detected in an average amount of 1.5 nmol ‐1 . The mean leukotriene E 4 /creatinine ratio in urine increased from 0.02 in healthy subjects to 0.11 in patients with liver cirrhosis and to 1.2 μmol leukotriene E 4 mol ‐1 creatinine in patients with hepatorenal syndrome. These results indicate that cysteinyl leukotrienes may play an important role in the mediator network responsible for the development of the hepatorenal syndrome in patients with severe liver disease.